Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.62 |
| ▸ | DRD3 | P35462 | 6/20 | 0.62 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5578178 | 0.99 | DRD2 (0.61) | DRD2DRD3OPRD1HDAC1HDAC4 | |
| SCHEMBL6800992 | 0.90 | DRD2 (0.50) | DRD2DRD3HTR1ACA1CA2 | |
| Hydrochloric Acid SCHEMBL5578018 | 0.89 | DRD2 (0.49) | DRD2DRD3HTR1ACA1CA2 | |
| Hydrochloric Acid SCHEMBL5578160 | 0.88 | DRD2 (0.55) | DRD2DRD3OPRD1HDAC1HDAC4 | |
| Hydrochloric Acid SCHEMBL5578415 | 0.84 | ACHE (0.57) | HTR1AMCHR1 | |
| SCHEMBL5578077 | 0.83 | MCHR1 (0.67) | DRD2DRD3OPRD1HDAC1HDAC4 | |
| Hydrochloric Acid SCHEMBL5578192 | 0.82 | MCHR1 (0.66) | DRD2DRD3OPRD1HDAC1HDAC4 | |
| Hydrochloric Acid SCHEMBL5578325 | 0.79 | DRD3 (0.45) | DRD2DRD3HTR1ACA1CA2 | |
| Hydrochloric Acid SCHEMBL5578185 | 0.78 | OPRD1 (0.52) | OPRD1HDAC1HDAC4 | |
| SCHEMBL6801333 | 0.78 | HTR2C (0.55) | OPRD1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063699-A1 | Gpr14 antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-01 | — | — | US | claimed |
| EP-1310490-A1 | GPR14 ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 2003-05-14 | — | — | EP | claimed |
| US-20040063699-A1 | Gpr14 antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1310490-A1 | GPR14 ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 2003-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063699-A1 | Gpr14 antagonist | GPR142, GPR139, GPR4 | DRD2 329/4885DRD3 433/4885OPRD1 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.